Press Releases

Found 268 Results
Page 1 of 27

Onxeo to Attend Key Investor and Scientific Conferences


Paris (France), January 11, 2021 – 7:00 am CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

01/11/2021


2020 – Full-year report on the liquidity contract


2020 Full-year report on the liquidity contract

01/08/2021


Onxeo Announces its Financial Agenda for 2021


Paris (France), January 7, 2021 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

01/07/2021



Onxeo Announces the Transfer of the Listing of its Shares to Euronext Growth Paris on December 15, 2020


Paris (France), December 10, 2020 – 6 pm CET – Onxeo S.A. (ISIN: FR0010095596), (“Onxeo” or “the Company”), a clinical-stage […]

12/10/2020




Onxeo Has Applied for Admission to Trading on Nasdaq First North Growth Market Denmark and Delisting from Nasdaq Main Market Copenhagen


Paris (France), November 27, 2020 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

11/27/2020


Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study and Positive Interim Results


The last patient was treated with AsiDNA™ in combination with carboplatin and paclitaxel in this Phase 1b study in patients […]

Tags:

11/09/2020


Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA™ Combined with PARP Inhibitors


This new patent protects the method of use of AsiDNA™ in combination with PARP inhibitors in the treatment of HR-proficient […]

Tags:

10/22/2020


Page 1 of 27